Press releases

ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, in Amsterdam, The Netherlands. The data being presented this year has a strong focus on novel exploratory therapeutic options and innovative treatment strategies, as well as improving awareness and understanding of key issues that continue to affect the HIV community.

Read more - ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018 Read more

Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof

GSK today announced that Dermavant Sciences, a subsidiary of Roivant Sciences, has agreed to purchase the rights to tapinarof, an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA) for the treatment of psoriasis and atopic dermatitis and back-up programmes for a total consideration of £250 million, including an initial payment of £150 million and a potential future milestone payment of £100 million.

Read more - Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof Read more